Halix, a contract development and manufacturing organization of clinical and commercial proteins and viral products, based in the Netherlands, announced the interim delivery of a new 6,700 m2 cGMP facility in Leiden Bio Science Park.
Leiden/The Netherlands — Following one year of construction, Halix has completed its new state-of-the-art cGMP facility for the development and production of biopharmaceutical drug substances.
The new five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000 Liter single-use bioreactors. In addition, lab space is available for process development, analytical development and quality control. All cleanroom areas have a unidirectional process flow and are designed to allow commercial manufacturing of biopharmaceuticals products.